
Sign up to save your podcasts
Or
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
4.5
242242 ratings
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
44,014 Listeners
32,103 Listeners
30,686 Listeners
26,180 Listeners
59,175 Listeners
4,128 Listeners
9,533 Listeners
9,641 Listeners
570 Listeners
14,420 Listeners
6,332 Listeners
5,142 Listeners
406 Listeners
73 Listeners
1,803 Listeners
4,422 Listeners
2,113 Listeners
80 Listeners
458 Listeners
2,288 Listeners
1,234 Listeners
231 Listeners
4,470 Listeners
491 Listeners
432 Listeners
148 Listeners
332 Listeners
374 Listeners
96 Listeners
78 Listeners
1,649 Listeners
254 Listeners
59 Listeners